DeepBio

Deep Bio is a South Korean healthcare technology company specializing in AI-driven diagnostics for cancer, particularly focusing on improving accuracy and efficiency in pathology assessments. The company develops in-vitro diagnostic software as medical devices that leverage deep learning to assist pathologists in delivering more accurate cancer diagnoses and prognoses, ultimately aiming for better patient outcomes in oncology. Their flagship product, DeepDx® Prostate, analyzes digitized slide images of H&E-stained prostate specimens to detect and localize prostate cancer lesions, provide automated histological grading based on the Gleason system, and quantify tumor involvement.

Deep Bio’s solutions are designed to address critical challenges in traditional pathology, such as the shortage of pathologists and diagnostic inconsistencies. By integrating state-of-the-art AI into clinical workflows, Deep Bio aims to provide fast, accurate, and consistent diagnostic support. Their technology has been clinically validated and has received regulatory approvals in South Korea and CE-IVD marking for Europe, with ongoing efforts for global expansion.